Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Multiple Myeloma

 

SNS01-T for Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma (2669)
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma or Diffuse Large B Cell Lymphoma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma , Lymphoma;    Status: Recruiting;   Study ID: NCT01435720

MLN9708 Plus Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (2606)
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01564537

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01503242

Carfilzomib and Pomalidomide With Dexamethasone for Relapsed or Refractory Multiple Myeloma (2512)
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Investigator: William Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01464034

Anti-CXCR4 (BMS-936564) Alone and in Combination for Relapsed/Refractory Multiple Myeloma (UW11025)
A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Investigator: Pamela Becker, MD, PhD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01359657

PCI-32765 for Relapsed or Relapsed and Refractory Multiple Myeloma (2694)
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01478581

SAR650984 for CD38+ Hematological Malignancies
A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies

Investigator: William Bensinger, MD;   Conditions: Hematological Malignancies;    Status: Recruiting;   Study ID: NCT01084252

ACY-1215 in Combination With Lenalidomide, and Dexamethasone for Multiple Myeloma
A Phase 1, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01583283